相关实验视频
Updated: Jun 29, 2025

Facile Preparation of 4-Substituted Quinazoline Derivatives
Published on: February 15, 2016
一种具有呼吸道放松效果和抗炎性质的新奇奇诺林
Jesper Bergwik1, Jielu Liu2, Médea Padra1
1Department of Clinical Sciences Lund, Respiratory Medicine, Allergology, & Palliative Medicine, Lund University and Skåne University Hospital, Lund, Sweden.
一种新类化合物RCD405在喘和COPD的临床前模型中表现出显著的呼吸道松和抗炎作用. RCD405降低了气道过敏反应和炎症,表明其作为慢性肺部疾病新疗法的潜力.
科学领域:
- 药理学 药理学是指药理学的学科.
- 呼吸系统医学 呼吸系统医学
- 药物发现 药物发现 药物发现
背景情况:
- 慢性肺部疾病,如喘和COPD需要改进治疗方法.
- 奎诺林是一种具有多种药理活动的化合物.
- 一种新型的素,RCD405,被调查其在治疗呼吸道疾病的潜力.
研究的目的:
- 为了评估RCD405在各种物种中的呼吸道松性质.
- 在过敏性喘和LPS诱导的炎症的小鼠模型中评估RCD405的抗炎作用.
- 探索RCD405.5的潜在作用机制.
主要方法:
- 在孤立的人,狗,老鼠和老鼠的气道中评估的气道放松.
- 在体内研究中使用了卵胺 (OVA) 诱导的喘和LPS诱导的炎症模型.
- 分析了呼吸道反应,免疫细胞招募,细胞因子/化学因子生产和基因表达.
- 在实验室中研究了NF-κB激活和细胞代谢.
主要成果:
- 在所有测试的物种中,RCD405表现出呼吸道放松作用.
- 在喘模型中,RCD405显著降低了气道过敏反应和OVA特异性IgE.
- 在OVA和LPS诱导的模型中,RCD405降低了炎症细胞招募和促炎媒介.
- 在体外,RCD405抑制了LPS诱导的NF-κB激活,并降低了细胞代谢.
结论:
- RCD405具有呼吸道放松剂和抗炎性质.
- 在临床前模型中,该化合物有效地减少了气道过敏反应和炎症.
- RCD405显示出作为潜在的治疗药物,可能通过NF-κB和代谢途径治疗炎症性呼吸道疾病.
更多相关视频
05:59Author Spotlight: Advancing Antimicrobial Resistance Research with Innovative Approaches and Synthetic Compounds
Published on: September 27, 2024
05:46A Novel Inhalation Mask System to Deliver High Concentrations of Nitric Oxide Gas in Spontaneously Breathing Subjects
Published on: May 4, 2021
相关概念视频
Antiasthma Drugs: Methylxanthines
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Antiasthma Drugs: Muscarinic Receptor Antagonists
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
Cholinergic Antagonists: Pharmacokinetics
Cholinergic Antagonists: Therapeutic Uses
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...